Denali Therapeutics (NASDAQ:DNLI) Releases Quarterly Earnings Results, Misses Expectations By $0.17 EPS

Denali Therapeutics (NASDAQ:DNLI) released its quarterly earnings results on Thursday. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.17), FiscalAI reports. The company had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $2.15 million. During the same quarter in the previous year, the business earned ($0.72) earnings per share.

Here are the key takeaways from Denali Therapeutics’ conference call:

• AVLAYAH generated $3.6 million in net product revenue during its first full commercial quarter, with commercial payer coverage exceeding 50% of covered lives. Denali expects Q3 revenue of $10 million–$12 million as access expands and more patients transition to treatment.
• Early launch indicators were stronger than anticipated, including high physician and family engagement and demand extending beyond the initially expected group of highly engaged families. Denali estimates roughly 375 U.S. pediatric patients are currently eligible, with additional opportunity from newly diagnosed children.
• Denali strengthened its balance sheet with $195 million from the sale of its Priority Review Voucher, bringing pro forma cash, cash equivalents, and marketable securities to more than $1.1 billion. Management said the capital supports AVLAYAH commercialization, pipeline development, manufacturing investments, and potential strategic flexibility.
• Two blood-brain-barrier Transport Vehicle programs for Alzheimer’s disease advanced into clinical development: DNL628, a tau antisense oligonucleotide, and DNL921, an anti-amyloid antibody. Initial biomarker and safety or proof-of-concept data are expected in 2027.
• Denali pushed DNL593 data to the first half of 2027, from an earlier expectation of year-end 2026, to obtain longer-term follow-up—particularly for neurofilament light-chain and other biomarkers—and assess a potential accelerated-approval strategy.

Denali Therapeutics Stock Up 0.4%

Shares of DNLI traded up $0.10 during trading on Friday, reaching $24.83. The company’s stock had a trading volume of 1,749,187 shares, compared to its average volume of 1,757,824. The company has a market cap of $3.94 billion, a price-to-earnings ratio of -8.74 and a beta of 1.01. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average of $23.54 and a two-hundred day moving average of $21.28. Denali Therapeutics has a twelve month low of $12.58 and a twelve month high of $27.30.

Analyst Ratings Changes

Several brokerages have issued reports on DNLI. Wedbush reaffirmed an “outperform” rating and issued a $26.00 price objective on shares of Denali Therapeutics in a research report on Monday, July 13th. UBS Group boosted their target price on shares of Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Friday, July 17th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Finally, Stifel Nicolaus set a $41.00 price target on shares of Denali Therapeutics in a research note on Monday, June 22nd. Thirteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $35.92.

Institutional Trading of Denali Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DNLI. Headlands Technologies LLC bought a new position in Denali Therapeutics during the 2nd quarter valued at $26,000. State of Wyoming bought a new stake in shares of Denali Therapeutics in the 2nd quarter worth about $29,000. Johnson Financial Group Inc. bought a new stake in shares of Denali Therapeutics in the 3rd quarter worth about $29,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Denali Therapeutics in the 4th quarter valued at about $57,000. Finally, Quarry LP acquired a new stake in shares of Denali Therapeutics in the 3rd quarter valued at about $64,000. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.